Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;73(1):78-88.
doi: 10.1016/j.lungcan.2010.10.020. Epub 2010 Dec 8.

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Giuseppe Luigi Banna  1 , Massimo Di Maio, Alessandro Follador, Elena Collovà, Jessica Menis, Silvia Novello, Emilio Bria; ISA Co-Authors; Mario Airoldi, Domenico Amoroso, Antonio Ardizzoia, Gaetano Aurilio, Emilio Bajetta, Pierluigi Ballardini, Fausto Barbieri, Emiddio Barletta, Maria Luisa Balzelloni, Umberto Basso, Ilaria Bernardini, Corrado Boni, Veronica Bordin, Sergio Bretti, Giuseppe Bronte, Cosimo Brunetti, Sebastiano Buti, Luigi Capanna, Alfredo Colombo, Giovanni Condemi, Diego Cortinovis, Mario Dambrosio, Concetta Di Fonzo, Giuseppe Di Lucca, Gianluca Dima, Amalia Falzetta, Adolfo Favaretto, Francesco Ferraù, Lucia Garetto, Vittorio Gebbia, Giovenzio Genestreti, Anna Lisa Gentile, Filippo Giovanardi, Roberto Labianca, Vito Lorusso, Giovanni Mantovani, Olga Martelli, Francesco Massari, Marta Mazzoli, Giovanni Michetti, Patrizia Mordenti, Claudia Mucciarini, Stefania Munao, Angelo Nacci, Claudia Pogliani, Giuseppe Procopio, Ferdinando Riccardi, Simona Rizzato, Antonio Rossi, Giovanni Rosti, Paola Russo, Tiziana Saladino, Nello Salesi, Domenico Santangelo, Teodoro Sava, Antonino Savarino, Francesca Spinnato, Marcello Tiseo, Ottaviano Tomassi, Luca Tondulli, Giuseppe Tonini, Salvatore Turano, Maria Rosaria Valerio, Franco Verderame, Francesca Zanelli, Elisa Zanon
Affiliations

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Giuseppe Luigi Banna et al. Lung Cancer. 2011 Jul.

Abstract

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤ 1). Post-operative radiotherapy (RT) is optional for pN2 tumours.

Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail.

Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians.

Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.

PubMed Disclaimer

MeSH terms

LinkOut - more resources